HID1-AS1: A Potential Drug Target and Biomarker (G102723641)

Target Name: HID1-AS1

NCBI ID: G102723641

HID1-AS1

Other Name(s): HID1 antisense RNA 1

HID1-AS1: A Potential Drug Target and Biomarker

HID1-AS1 is a non-coding RNA molecule that has been identified using RNA-seq technology as highly expressed in various tissues and organs, including brain, heart, muscle, and pancreas. It is part of the HID1 gene family, which has been implicated in a number of cellular processes, including cell signaling, cell death, and tissue repair. In this article, we will explore the potential implications of HID1-AS1 as a drug target and biomarker.

The HID1 gene family is composed of four splice variants, HID1-AS1, HID1-AS2, HID1-AS3, and HID1-AS4. HID1-AS1 is the most abundant member of the family, accounting for up to 80% of the total RNA expression in some cell types. The other three splice variants are expressed at much lower levels.

HID1-AS1 is a small non-coding RNA molecule that contains 194 amino acid residues. It is expressed in various tissues and organs, including brain, heart, muscle, and pancreas. HID1-AS1 has been shown to play a role in a number of cellular processes, including cell signaling, cell death, and tissue repair.

One of the key functions of HID1-AS1 is its role in cell signaling. HID1-AS1 has been shown to interact with several protein molecules, including the transcription factor p300 and the protein kinase AGO2. These interactions suggest that HID1-AS1 may play a role in regulating the activity of these molecules, which could have implications for a number of cellular processes.

Another function of HID1-AS1 is its role in cell death. HID1-AS1 has been shown to be involved in the regulation of cell apoptosis, which is a natural process that helps remove damaged or dysfunctional cells from the body. This suggests that HID1-AS1 may play a role in protecting cells from apoptosis, which could have implications for a number of diseases.

In addition to its role in cell signaling and cell death, HID1-AS1 is also involved in tissue repair. HID1-AS1 has been shown to play a role in the regulation of cell proliferation, which is a critical process for tissue repair and regeneration. This suggests that HID1-AS1 may be involved in repairing damaged tissue, which could have implications for a number of diseases.

As a potential drug target, HID1-AS1 is an attractive target for drug developers because of its involvement in multiple cellular processes that are important for human health. In addition, because HID1-AS1 is expressed in a wide variety of tissues and organs, it is less likely to have unintended consequences in other parts of the body.

In addition to its potential as a drug target, HID1-AS1 may also be a useful biomarker for a number of diseases. For example, HID1-AS1 has been shown to be involved in the regulation of cell apoptosis, which is a critical process for tissue repair and regeneration. This suggests that HID1-AS1 may be a useful biomarker for a number of diseases, including cancer, neurodegenerative diseases, and diseases of the immune system.

In conclusion, HID1-AS1 is a non-coding RNA molecule that has been identified using RNA-seq technology as highly expressed in various tissues and organs. It is part of the HID1 gene family and has been shown to play a role in cell signaling, cell death, and tissue repair. As a potential drug target and biomarker, HID1-AS1 is an attractive target for drug developers because of its involvement in multiple cellular processes that are important for human health. Further research is needed to fully understand the role of HID1-AS1 in

Protein Name: HID1 Antisense RNA 1

The "HID1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HID1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets